<DOC>
	<DOCNO>NCT01095731</DOCNO>
	<brief_summary>The purpose phase II study ass safety tiopronin aneurysmal subarachnoid hemorrhage ( aSAH ) patient order obtain preliminary data efficacy tiopronin versus placebo reduce serum cerebrospinal fluid ( CSF ) 3AP level patient population . Funding Source - FDA Office Orphan Products Development</brief_summary>
	<brief_title>The Effects Tiopronin 3-Aminopropanal Level &amp; Neurologic Outcome After Aneurysmal Subarachnoid Hemorrhage</brief_title>
	<detailed_description>The annual rate aSAH United States approximately 18 24 thousand case year . Mortality rate follow aSAH range 30-70 % 10-20 % survivor experience severe neurological disability . Following aSAH , major cause morbidity mortality vasospasm , cause delayed ischemic neurologic deterioration . There currently effective treatment prevent ameliorate damage occur follow cerebral ischemia . A myriad neuro-toxins produce ischemic brain result vicious cycle cellular death destruction . The polyamines spermine spermidine metabolize polyamine oxidase ( PAO ) putrescine 3-aminopropanal ( 3AP ) . Tiopronin ( Thiola ) FDA approve drug use treatment cystine stone patient cystinuria U.S . In Europe , also use treatment rheumatoid arthritis bronchial hypersecretion . In previous animal study , demonstrate tiopronin able bind neutralize toxic effect 3AP . We show previous study aSAH patient elevate 3AP level , high level correlate poor neurologic outcome . The goal phase II multicenter , randomize , double-blinded safety efficacy trial ( 1 ) evaluate safety drug patient population dose establish phase I ; ( 2 ) demonstrate tiopronin cross blood-brain barrier ; ( 3 ) show serum CSF 3AP level reduce administration tiopronin ; ( 4 ) demonstrate reduction 3AP level associate improved neurologic outcome aSAH patient .</detailed_description>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Subarachnoid Hemorrhage</mesh_term>
	<mesh_term>Glycine</mesh_term>
	<mesh_term>Retinol acetate</mesh_term>
	<criteria>Admitted recruiting center aneurysmal subarachnoid hemorrhage Ability initiate study drug treatment within 96 hour aSAH onset . Ability provide either informed surrogate consent Hypersensitivity penicillamine Creatinine level great 1.5/mm^3 admission Platelet count le 100,000/mm^3 admission White blood cell count le 3.5/mm^3 admission AST ALT great 60/L admission history liver failure Pregnancy History lupus , Goodpasture 's syndrome , myasthenia gravis , pemphigus , nephrotic syndrome , glomerulonephritis , renal failure Patients consider unable comply protocol</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>aneurysm</keyword>
	<keyword>aneurysmal</keyword>
	<keyword>subarachnoid</keyword>
	<keyword>hemorrhage</keyword>
	<keyword>haemorrhage</keyword>
	<keyword>neuroprotection</keyword>
	<keyword>3-aminopropanal</keyword>
	<keyword>3AP</keyword>
	<keyword>polyamine oxidase</keyword>
	<keyword>spermine</keyword>
	<keyword>spermidine</keyword>
	<keyword>vasospasm</keyword>
	<keyword>cerebral ischemia</keyword>
	<keyword>neurosurgery</keyword>
	<keyword>neurological intensive care unit</keyword>
	<keyword>NICU</keyword>
	<keyword>Tiopronin</keyword>
	<keyword>Thiola</keyword>
	<keyword>FDA</keyword>
	<keyword>Thiopronin</keyword>
	<keyword>Thiosol</keyword>
	<keyword>Tioglis</keyword>
	<keyword>Acadione</keyword>
	<keyword>Capen</keyword>
	<keyword>Captimer</keyword>
	<keyword>Epatiol</keyword>
	<keyword>Vincol</keyword>
	<keyword>Mucolysin</keyword>
	<keyword>Sutilan</keyword>
	<keyword>Meprin</keyword>
	<keyword>Thiolpropionamidoacetic acid</keyword>
	<keyword>Mercaptopropionyl glycine</keyword>
	<keyword>2 MPG</keyword>
</DOC>